- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03484221
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
Totally Neoadjuvant FOLFOXIRI Chemotherapy Followed by Short-course Radiation and XELOX Chemotherapy in Patients With Locally Advanced Rectal Cancer:an Open-label, Single-arm, Multicenter Phase II Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Neoadjuvant chemoradiation therapy with double cytotoxic agents is the standard treatment for the patients with locally advanced rectal cancer. Conventional treatment reduced the local recurrence but did not prolong the long-term survival. Furthermore, the patients with pathological complete response (pCR) did not benefit from double cytotoxic chemotherapy. Therefore, we chose triple cytotoxic agents FOLFOXIRI as the neoadjuvant chemotherapy. We will evaluate the efficacy and safety of totally neoadjuvant FOLFOXIRI chemotherapy (irinotecan, oxaliplatin and fluorouracil) followed by short-course radiation and XELOX chemotherapy in the patients with locally advanced rectal cancer to achieve more pCR and longer survival.
In this prospective study, 30 patients with locally advanced rectal cancer will be recruited. Firstly, 4 cycles of neoadjuvant FOLFOXIRI chemotherapy were administered. Subsequently, a short-course radiation therapy (5Gy*5) will be performed. After that, 4 cycles of XELOX chemotherapy will be administered followed by TME surgery. PET-CT examination will be performed before and after the 4 cycles of neoadjuvant FOLFOXIRI chemotherapy to assess the SUVmax changes. In addition, the dynamic changes of ctDNA in peripheral blood will be monitored at the PET-CT examination. In the course of treatment, safety evaluation will be carried out according to the standard of adverse reaction classification (CTCAE) 4.0.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yuanhe Wang, PhD
- Phone Number: 18900918794
- Email: zhangjd0228@hotmail.com
Study Locations
-
-
-
Shenyang, China
- Recruiting
- China Medical University
-
Contact:
- Yuanhe Wang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18-75 years old
- Primary and pathological diagnosis of rectal adenocarcinoma
- Radiographic evaluation of initial resectable rectal cancer
- T staging was determined by MRI as T3N+ or T4Nx
- Distal border of the tumor must be located < 12 cm from the anal verge
- ECOG status: 0~1
- Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment:
Neutrophil count≥1.5×10^9/L Platelet count≥90×10^9/L Hemoglobin≥90g/L Total bilirubin (TBI) ≤ 1.5 * ULN Alanine aminotransferase (ALT)≤2.5 * ULN Aspartate aminotransferase (AST)≤2.5 * ULN Alkaline phosphatase (ALP)≤2.5 * ULN
- Signed informed consent; able to comply with study and/or follow- up procedures
Exclusion Criteria:
- Previous treatment with oxaliplatin, irinotecan or fluorouracil
- Hypersensitivity to fluorouracil, oxaliplatin or irinotecan.
- Clear indication of involvement of the pelvic side walls by imaging
- With distant metastasis
- A history of malignant rectal cancer (i. e. sarcoma, lymphoma, carcinoid, squamous cell carcinoma) or synchronous colon cancer
- Cardiovascular disease that would preclude study treatment or follow-up; New York Heart Association class III or IV heart disease; active ischemic heart disease; myocardial infarction within the past 6 months; symptomatic arrhythmia uncontrolled hypertension. Unexplained syncope occurred within 3 months
- Digestive system diseases that would preclude study treatment or follow-up within the past 6 months
- Gastric ulcers or duodenal ulcers for the treatment of resistance;
- 3 or 4 grade gastrointestinal bleeding / bleeding;
- Gastrointestinal perforation / fistula;
- Abdominal abscess;
- Infectious or inflammatory bowel disease
- HIV infection and/or active hepatitis B virus infection
- Pregnant or lactating women. Fertile patients must use effective contraception
- Any serious acute or chronic disease that can not be involved in the study or to influence the interpretation of the results of the study
- Other intervention clinical trials were combined at the same time.
- Nerve or mental abnormality affecting cognitive ability
- Other malignancy except effectively treated squamous cell or basal cell skin cancer,
- Other situations that the researchers think should be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FOLFOXIRI+short-course radiation+XELOX
Firstly, 4 cycles of neoadjuvant FOLFOXIRI chemotherapy were administered.
Subsequently, a short-course radiation therapy (5Gy*5) will be performed.
After that, 4 cycles of XELOX chemotherapy will be administered followed by surgery.
|
IRINOTECAN 150 mg/m^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
Other Names:
Patients received a short-course radiation therapy(5Gy*5) after 4 cycles of FOLFOXIRI.
OXALIPLATIN 130 mg/m^2 IV over 2-h, day 1 Capecitabine 1000 mg/m^2 twice daily days 1-14 every 3 weeks for 4 cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The ratio of tumor downstaging to stage 0 and stage I
Time Frame: 2 years
|
Tumor downstaging from stage II or III to pathologic complete response (stage 0) and stage I
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor regression grade (TRG)
Time Frame: 2 years
|
The level of tumor regression under pathological examination
|
2 years
|
Disease free survival
Time Frame: 3 years
|
Estimated from the date of surgery to the date of recurrence.
|
3 years
|
Overall survival time
Time Frame: 3 years
|
Estimated from the date of enrollment to death from any cause.
|
3 years
|
Quality of life (QLQ C30)
Time Frame: Every 2 weeks after the first treatment until 3 years
|
Scores according to EORTC QLQ-C30 scoring manual
|
Every 2 weeks after the first treatment until 3 years
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: 3 years
|
The grade of toxicity will be assessed using the NCI-CTCAE version 4.0.
|
3 years
|
ctDNA change
Time Frame: 3 years
|
The relationship between ctDNA and survival will be evaluated.
|
3 years
|
SUVmax changes
Time Frame: At the beginning of Cycle 1 and the end of Cycle 4 (each cycle is 14 days)
|
Tumor metabolic response through FDG-PET examination before and after 4 cycles of neoadjuvant FOLFOXIRI chemotherapy
|
At the beginning of Cycle 1 and the end of Cycle 4 (each cycle is 14 days)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Rectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Fluorouracil
- Capecitabine
- Oxaliplatin
- Irinotecan
Other Study ID Numbers
- LGIOG-2017-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Neoplasms
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
SafeHeal IncTerminatedSafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study (SAFE-2)Colorectal Cancer | Rectal Cancer | Rectal Tumor | Rectal/AnalUnited States, France, Belgium
-
National Cancer Institute (NCI)TerminatedStage III Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage II Rectal Cancer AJCC v8 | Locally Advanced Rectal CarcinomaUnited States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
-
National Cancer Institute (NCI)NRG OncologyCompletedRectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage II Rectal Cancer AJCC v7United States, Puerto Rico
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Peking University Third HospitalRecruitingRectal Cancer Stage II | Rectal Cancer Stage IIIChina
-
Prof. Dr. med. Claus RödelJohann Wolfgang Goethe University Hospital; Deutsche Krebshilfe e.V., Bonn...CompletedRectal Neoplasms | Rectal Cancer Stage II | Rectal Cancer Stage IIIGermany
-
National Cancer Institute (NCI)CompletedRectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage II Rectal Cancer AJCC v7United States
Clinical Trials on FOLFOXIRI
-
Azienda Ospedaliero, Universitaria PisanaCompletedPancreatic Carcinoma Stage IIIItaly
-
Fujian Cancer HospitalNot yet recruitingAdvanced Colorectal Cancer
-
AIPING ZHOUCompletedLocally Advanced Rectal CancerChina
-
Catharina Ziekenhuis EindhovenNot yet recruiting
-
Kasr El Aini HospitalCompletedMetastatic Colorectal CancerEgypt
-
Gruppo Oncologico del Nord-OvestCompletedMetastatic Colo-rectal CancerItaly
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingRectal Cancer | Chemotherapy Effect
-
Fudan UniversityRecruitingColorectal Cancer | Vitamin C | GLUT3China
-
Gruppo Oncologico del Nord-OvestCompletedMetastatic Colorectal CancerItaly
-
Sun Yat-sen UniversityNot yet recruiting